Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT07177209

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population — Recruiting • Rheumatology • NCT07177209.

📅 27 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07177209
Sponsor
Pfizer
Start
2026-04-01
ClinicaliQ Trial Snapshot
  • Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population — Recruiting • Rheumatology • NCT07177209.
  • Sponsor: Pfizer.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Eligibility Snapshot
  • Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
  • Patient enrolled in IBD registry from 2009 2. >18 years at time of diagnosis. 3. Diagnosis of Ulcerative Colitis.
  • Patient data entered during the study period. 5. Minimum duration of data post UC diagnosis (Cohort A: 6 months, Cohort B-D 6 months)

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Webinar
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 0.5 · 05 Apr 2026
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL Surveillance safety signals, cardiovascular…
Watch webinar →
Podcast
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 00:16:21 · 03 Apr 2026
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk assessment after higher rates…
Listen →
Guideline
Osteoarthritis: Care and Management (NICE CG177)
Rheumatology · 27 Mar 2026
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before…
View guideline →
Guideline
Axial Spondyloarthritis: Diagnosis and Management (NICE NG65)
Rheumatology · 27 Mar 2026
Refer adults to rheumatology if they present with chronic back pain (≥3 months) plus any of: inflammatory back pain features, elevated inflammatory…
View guideline →
Guideline
Psoriatic Arthritis: Assessment and Management (NICE NG65)
Rheumatology · 27 Mar 2026
Refer to rheumatology for diagnostic assessment if psoriatic arthritis is suspected in patients with psoriasis and joint symptoms, regardless of psoriasis severity…
View guideline →
Guideline
Gout: Diagnosis and Management (NICE NG219)
Rheumatology · 27 Mar 2026
Diagnose acute gout clinically (sudden joint pain, erythema, swelling) and confirm with serum urate level plus polarising microscopy of synovial fluid showing…
View guideline →